TY - JOUR
T1 - Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis
AU - Del Rio, M.
AU - McCracken, G. H.
AU - Nelson, J. D.
AU - Chrane, D.
AU - Shelton, S.
PY - 1982
Y1 - 1982
N2 - Single-dose pharmacokinetics of ceftriaxone were determined in 19 patients with proven bacterial meningitis. The dosage was 50 mg of ceftriaxone per kg. The plasma concentration time curve declined in a biexponential manner. The mean peak plasma concentration was 207 μg/ml, and the elimination half-life was 4 h. In 12 patients, multiple-dose pharmacokinetics were determined after a loading dose of 75 mg of ceftriaxone per kg, followed by 50-mg/kg doses every 8 h in 5 patients or every 12 h in 7 patients. The mean peak plasma concentration was 230 μg/ml after the first dose and 263 μg/ml after the last dose. Of 12 patients, 5 had trough values that were larger after multiple doses than after a single dose. Mean penetration of ceftriaxone into cerebrospinal fluid was 3.1%. The median cerebrospinal fluid bacterial titer against the patients pathogens was >1:1,024 and <1:2,048. The drug was well tolerated without adverse effects.
AB - Single-dose pharmacokinetics of ceftriaxone were determined in 19 patients with proven bacterial meningitis. The dosage was 50 mg of ceftriaxone per kg. The plasma concentration time curve declined in a biexponential manner. The mean peak plasma concentration was 207 μg/ml, and the elimination half-life was 4 h. In 12 patients, multiple-dose pharmacokinetics were determined after a loading dose of 75 mg of ceftriaxone per kg, followed by 50-mg/kg doses every 8 h in 5 patients or every 12 h in 7 patients. The mean peak plasma concentration was 230 μg/ml after the first dose and 263 μg/ml after the last dose. Of 12 patients, 5 had trough values that were larger after multiple doses than after a single dose. Mean penetration of ceftriaxone into cerebrospinal fluid was 3.1%. The median cerebrospinal fluid bacterial titer against the patients pathogens was >1:1,024 and <1:2,048. The drug was well tolerated without adverse effects.
UR - http://www.scopus.com/inward/record.url?scp=0020449995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020449995&partnerID=8YFLogxK
U2 - 10.1128/AAC.22.4.622
DO - 10.1128/AAC.22.4.622
M3 - Article
C2 - 6295262
AN - SCOPUS:0020449995
VL - 22
SP - 622
EP - 627
JO - Seminars in Fetal and Neonatal Medicine
JF - Seminars in Fetal and Neonatal Medicine
SN - 1744-165X
IS - 4
ER -